Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study
- 1 November 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 163 (5), 757-763
- https://doi.org/10.1530/eje-10-0553
Abstract
Objective: To study whether post-surgical and/or post-ablative thyroglobulin (Tg) concentrations may serve as independent predictors of disease recurrence in patients treated for TNM stage I or II well-differentiated thyroid carcinoma (WDTC).Design: An observational retrospective study with a median follow-up of 16 years (range 10–24).Patients and measurements: Post-operative and post-ablative Tg concentrations, age, tumour size, local infiltration and nodal metastasis at primary surgery as well as disease recurrences and cancer-specific deaths were evaluated in 495 low-risk (TNM stages I and II) patients, the majority of whom had total thyroidectomy and radioactive iodine remnant ablation as initial treatment.Results: Fifty-one patients (10.3%) experienced disease recurrence during follow-up. In multiple logistic regression analysis, post-ablative Tg concentrations (odds ratio (OR) 3.72, confidence interval (CI) 1.71–8.05, P=0.0009) and local infiltration on primary surgery (OR 2.66, CI 1.03–6.90, P=0.04) were the only independent predictors of recurrence.Conclusions: Post-ablative Tg concentration is a strong predictor of disease recurrence in WDTC.Keywords
This publication has 16 references indexed in Scilit:
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institutionAnnals Of Oncology, 2009
- Prophylactic Lymph Node Dissection for Papillary Thyroid Cancer Less Than 2 cm: Implications for Radioiodine TreatmentJournal of Clinical Endocrinology & Metabolism, 2009
- Long‐term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatmentClinical Endocrinology, 2008
- Management of Patients With Low-Risk Papillary Thyroid CarcinomaEndocrine Practice, 2007
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumActa Endocrinologica, 2006
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006
- Prognostic Factors for Persistent or Recurrent Disease of Papillary Thyroid Carcinoma with Neck Lymph Node Metastases and/or Tumor Extension beyond the Thyroid Capsule at Initial DiagnosisJournal of Clinical Endocrinology & Metabolism, 2005
- Current Approaches to Primary Therapy for Papillary and Follicular Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2001
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998